Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Biodesix Inc.
Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Kiadis Pharma.
Interrupting Ebola Tracey Baas doi:10.1038/scibx.2014.1088 Although different companies are pursuing antibodies, vaccines or siRNAs to fight Ebola, many researchers believe it is not a race between them but a combination of approaches that will win the day. Full Text | PDF
Canadian accelerant Lauren Martz doi:10.1038/scibx.2014.1089 Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs. Full Text | PDF
ALK7's obese functions Chris Cain doi:10.1038/scibx.2014.1090 Researchers have shown that inhibiting ALK7 can increase energy expenditure in fat cells and suggest the protein could be a target for obesity. Acceleron Pharma has licensed the findings and is pursuing a discovery program for ALK7 antagonists. Full Text | PDF
Transforming growth factor-β1 (TGFB1) doi:10.1038/scibx.2014.1092 Studies in mice and patient samples suggest antagonizing TGFB1 signaling could help treat medulloblastoma. Full Text | PDF
Aurora kinase A (AURKA; aurora-A); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC) doi:10.1038/scibx.2014.1093 Mouse and in vitro studies have identified compounds that disrupt the catalytic activity and active conformation of aurora-A and could be useful for treating MYCN-driven cancers. Full Text | PDF
AXL receptor tyrosine kinase (AXL; UFO) doi:10.1038/scibx.2014.1094 Mouse and cell culture studies suggest combination treatment with AXL inhibitors and anti-mitotic agents could help treat cancer drug resistance associated with the epithelial-to-mesenchymal transition. Full Text | PDF
AXL receptor tyrosine kinase (AXL; UFO); epidermal growth factor receptor (EGFR) doi:10.1038/scibx.2014.1095 Mouse and cell culture studies suggest AXL inhibitors could help circumvent resistance to the anti-EGFR mAb Erbitux cetuximab. Full Text | PDF
CXC chemokine receptor 2 (CXCR2; IL8RB); lymphocyte antigen 6 complex locus G (LY6G; GR1) doi:10.1038/scibx.2014.1096 Mouse and cell culture studies suggest blocking recruitment of GR1+ myeloid cells to tumors could help prevent chemotherapy resistance. Full Text | PDF
DnaJ homolog subfamily B member 11 (DNAJB11; ERdj3); glucocerebrosidase (GBA; GCase) doi:10.1038/scibx.2014.1097 Mouse studies suggest inhibiting ERdj3 could help treat Gaucher's disease, a lysosomal storage disorder caused by loss-of-function mutations in GCase. Full Text | PDF
Activin A receptor type 1C (ACVR1C; ALK7) doi:10.1038/scibx.2014.1098 Mouse studies suggest inhibiting ALK7 in adipose tissue could help treat obesity. Full Text | PDF
Ebola glycoprotein GP1; Ebola glycoprotein GP2 doi:10.1038/scibx.2014.1099 Guinea pig and nonhuman primate studies suggest ZMapp could help treat Ebola virus infection. Full Text | PDF
Ebola glycoprotein GP1; Ebola glycoprotein GP2 doi:10.1038/scibx.2014.1100 Nonhuman primate studies suggest a prime-boost vaccination regimen using chimpanzee-derived replication-defective adenovirus 3 (ChAd3) vectors and modified vaccinia Ankara (MVA) vectors that both encode Ebola glycoproteins could help protect against Ebola infection. Full Text | PDF
HIV gp120; HIV gp41 doi:10.1038/scibx.2014.1101 In vitro studies suggest a small molecule inhibiting the HIV envelope glycoprotein could be useful for developing broadly acting HIV drugs. Full Text | PDF
HIV gp120; HIV gp41 doi:10.1038/scibx.2014.1102 Studies in patient samples and in vitro suggest the broadly neutralizing antibody (bNAb) 35O22 could help treat HIV. Full Text | PDF
Multiple virulence factor regulator (MvfR) doi:10.1038/scibx.2014.1103 Mouse and cell culture studies have identified benzamide-benzimidazole–based inhibitors of MvfR that could help treat Pseudomonas aeruginosa infection. Full Text | PDF
Phospholipase A2 group IVA cytosolic calcium-dependent (PLA2G4A; cPLA2-α) doi:10.1038/scibx.2014.1104 Rodent and cell culture studies have identified a series of 3-(1-aryl-1H-indol-5-yl) propanoic acid–based cPLA2-α inhibitors that could help treat inflammatory conditions. Full Text | PDF
Not applicable doi:10.1038/scibx.2014.1105 Studies in humans suggest targeted, noninvasive electromagnetic stimulation to modulate cortical-hippocampal networks could help improve associative memory. Full Text | PDF
Aldehyde dehydrogenase 2 family mitochondrial (ALDH2) doi:10.1038/scibx.2014.1106 Rodent studies suggest stimulating ALDH2 could help treat pain. Full Text | PDF
Activity-directed synthesis of bioactive scaffolds doi:10.1038/scibx.2014.1107 Activity-directed synthesis could enhance the efficiency of bioactive scaffold discovery. Full Text | PDF
Cell membrane–cloaked polymeric nanoparticles to clear autoreactive antibodies associated with autoimmune diseases doi:10.1038/scibx.2014.1108 Nanoparticles cloaked in cell membranes could help clear autoreactive antibodies associated with autoimmune conditions such as hemolytic anemia and immune thrombocytopenia. Full Text | PDF
Clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing to cure latent viral infections doi:10.1038/scibx.2014.1109 CRISPR-Cas9 genome editing could be used to help treat latent viral infections. Full Text | PDF
Cultured human muscle satellite cells to restore gene function in muscular dystrophies doi:10.1038/scibx.2014.1110 Cell culture and mouse studies suggest cultured human muscle satellite cells could be used to restore gene function to treat muscular dystrophies. Full Text | PDF
Nanoparticle-based imaging system using the metadherin (MTDH; AEG1) promoter to image prostate cancer doi:10.1038/scibx.2014.1111 A nanoparticle-based imaging system that uses the AEG1 promoter could be useful for detecting metastatic prostate cancer. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment